PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.78%
EBIT growth above 1.5x AXSM's 23.84%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
74.78%
Operating income growth above 1.5x AXSM's 35.57%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
64.85%
Net income growth above 1.5x AXSM's 19.26%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
64.71%
EPS growth above 1.5x AXSM's 20.49%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
64.71%
Diluted EPS growth above 1.5x AXSM's 20.49%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-60.52%
Negative OCF growth while AXSM is at 25.25%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-60.52%
Negative FCF growth while AXSM is at 25.25%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
51.61%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
51.61%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
51.61%
3Y OCF/share CAGR above 1.5x AXSM's 23.58%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
66.06%
Positive 10Y CAGR while AXSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
66.06%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
66.06%
3Y net income/share CAGR above 1.5x AXSM's 11.48%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.06%
Negative asset growth while AXSM invests at 7.23%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-5.28%
We have a declining book value while AXSM shows 35.76%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
11.50%
Debt growth far above AXSM's 2.81%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-73.61%
We cut SG&A while AXSM invests at 7.86%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.